• Vaccine Ontology ID: VO_0004024
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant GlpQ
• GlpQ gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001238
• Vector: pET-3a vector (Cameron et al., 1998).
• Immunization Route: IM, SC, IP, and ID

• Vaccine Ontology ID: VO_0004026
• Type: Subunit vaccine
• Status: Research
• Antigen: 125 μg of purified intact ORF recombinant Tp92 (Cameron et al., 2000).
• tp92 gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001238
• Immunization Route: i.m., s.c., i.p., and i.d.

Rabbit Response

• Host Strain: New Zealand White
• Vaccination Protocol: Rabbits were immunized three times (IM, SC, IP, and ID) at 3-week intervals with the Ribi MPL + TDM + CWS adjuvant and 100 μg of purified inclusion bodies from E. coli expressing either the pET-3a vector alone or the Gpd-pET-3a construct (Cameron et al., 1998).
• Challenge Protocol: Two weeks after administration of the final immunization, rabbits were challenged ID at each of six sites on their shaved backs with 103 T. pallidum per site (Cameron et al., 1998).
• Efficacy: Immunization with the recombinant GlpQ significantly protected rabbits from subsequent T. pallidum challenge, altering lesion development at the sites of challenge. All eight control rabbits developed typical red, raised, and highly indurated lesions at each of the six challenge sites that in some cases progressed to ulceration. All four of the Gpd-immunized rabbits developed atypical pale, flat, slightly indurated, and nonulcerative reactions at each of the six challenge sites. In all cases, induration in the Gpd-immunized animals resolved before lesions appeared in the control animals and resembled delayed-type hypersensitivity responses more than typical syphilis chancres (Cameron et al., 1998).

Rabbit Response

• Host Strain: New Zealand White
• Vaccination Protocol: New Zealand White rabbits were immunized (intramuscularly, subcutaneously, intraperitoneally, and intradermally) at 3‐week intervals with Ribi adjuvant and 125 μg of purified intact ORF recombinant Tp92. Unimmunized rabbits were used as a control (Cameron et al., 2000).
• Challenge Protocol: At 1–4 weeks after administration of the final immunization in each protection experiment, the immunized rabbits and a total of 4 unimmunized control rabbits were subjected to intradermal challenge at each of 8 sites on their shaved backs with 10^5 T. pallidum subsp. pallidum (Nichols strain) per site. The rabbits were examined daily to monitor the development, morphologic appearance, and progression of lesions appearing at the challenge sites (Cameron et al., 2000).
• Efficacy: Immunization with recombinant Tp92 partially protected rabbits from subsequent T. pallidum challenge. the rabbits immunized with the T. pallidum recombinant Tp92 before challenge all demonstrated alteration of lesion development. Significant attenuation of lesion development was observed in these rabbits, with atypical pale, flat, slightly indurated, and for the most part, nonulcerative lesions appearing at the sites of challenge. In these protection experiments, the number of lesions progressing to ulceration and the number of darkfield‐positive lesions in the Tp92‐immunized rabbits were significantly smaller than those of lesions appearing in the control animals (Cameron et al., 2000).